Boston Scientific (BSX) is back in focus after strong Q1 2026 results coincided with lower guidance and fresh clinical data around its FARAPULSE pulsed field ablation and WATCHMAN left atrial appendage closure platforms.

Despite strong Q1 numbers and encouraging FARAPULSE and WATCHMAN clinical updates, Boston Scientific’s recent guidance cut and analyst downgrades have weighed on sentiment, with a 7 day share price return of -8.97% and a 1 year total shareholder return of -46.15% both negative, while the 5 year total shareholder return of 31.00% points to a stronger longer term record.

If this mix of clinical results and shifting expectations has you thinking about where else capital could go to work, it might be worth scanning other healthcare names tied to artificial intelligence through the 33 healthcare AI stocks.

With Boston Scientific now trading well below recent highs despite clinical and earnings momentum, the key issue is whether current weakness reflects an undervalued medtech leader or if the market already prices in future growth potential.

Most Popular Narrative: 42.9% Undervalued

Boston Scientific’s most followed narrative pegs fair value at $98.90 versus the last close of $56.50, a wide gap that draws attention to how future growth and margins are being framed according to Bill_S.

The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons:

• Earnings Dilution: The acquisition is expected to be dilutive to adjusted earnings per share (EPS) by approximately $0.06 to $0.08 in the first full year. Investors often react to this "EPS drag" by pulling back, which we have seen in the recent price dips.
• Increased Debt Load: BSX is financing a significant portion of this deal (about $11 billion) with new debt. This has raised concerns about the company’s leverage, with projections hitting 3.3x adjusted EBITDA leverage by the end of 2026.

Want to see how this earnings drag, higher leverage and fast growing thrombectomy exposure still support a higher fair value? The narrative leans on a specific growth glide path, expanding margins and a premium profit multiple to justify that gap.

Result: Fair Value of $98.90 (UNDERVALUED)

However, investors still need to watch for slower integration of Penumbra and for any setbacks in FARAPULSE or WATCHMAN data that could challenge the upbeat valuation case.

Next Steps

With mixed sentiment running through this story, now is a good moment to look at the underlying data yourself and move quickly to form a balanced view using the 5 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Boston Scientific has sharpened your thinking, do not stop here. Use the Simply Wall St Screener to size up fresh opportunities before the crowd moves.

• Target quality at a discount by scanning 51 high quality undervalued stocks that pair solid fundamentals with prices below their estimated worth.
• Prioritise resilience with 67 resilient stocks with low risk scores that score well on stability and balance sheet strength.
• Spot potential future leaders early through the screener containing 25 high quality undiscovered gems that are not yet widely followed by the market.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.